| Similar Articles |
|---|
 |
The Motley Fool
July 23, 2007
Brian Lawler |
Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again.   |
The Motley Fool
June 4, 2007
Brian Lawler |
Progenics Is on the Clock The biotech's marketing application for its lead compound gets accepted for review. Investors, take note. |
The Motley Fool
March 9, 2007
Brian Lawler |
Progenics Gets Backed Up Progenics Pharmaceutics and drugmaker giant Wyeth announced a delay in one of their methylnaltrexone programs. Investors, take note. |
The Motley Fool
October 15, 2009
Brian Orelli |
This Partnership Will Go No Further Wyeth and Progenics call it quits. |
The Motley Fool
March 13, 2008
Brian Orelli |
Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note. |
The Motley Fool
September 13, 2007
Brian Orelli |
Progenics Progresses Progenics and partner Wyeth announce plans to start three new clinical trials on their constipation-relieving drug. The patient treatment time for the trials is relatively short, so investors won't have to wait too long to see how the drug performs. |
The Motley Fool
April 25, 2008
Brian Orelli |
Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation. |
The Motley Fool
May 23, 2008
Brian Orelli |
Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data. |
The Motley Fool
September 22, 2009
Brian Orelli |
Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
September 5, 2006
Brian Lawler |
Adolor: Positive Results, Negative Reaction The market seems confused by good results from Adolor's latest clinical trial. Investors willing to take a gamble on Adolor at this price may be in for huge rewards if the company and Glaxo can convince the FDA of Entereg's viability. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
The Motley Fool
November 28, 2008
Brian Orelli |
Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug? |
The Motley Fool
January 20, 2004
David Nierengarten |
Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results. |
The Motley Fool
April 23, 2008
Brian Orelli |
Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
The Motley Fool
January 24, 2008
Brian Lawler |
Adolor Advisory Panel Aftermath An FDA advisory panel votes favorably on Adolor's lead drug. |
The Motley Fool
December 20, 2011
Brian D. Pacampara |
Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor. |
The Motley Fool
July 25, 2008
Brian Orelli |
Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug. |
